Drug Profile
Research programme: influenza virus vaccine - HepaLife
Latest Information Update: 23 Dec 2010
Price :
$50
*
At a glance
- Originator HepaLife Technologies
- Class
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Influenza virus infections
Most Recent Events
- 10 Jul 2006 Preclinical trials in Influenza virus infections in USA (Injection)